Severe blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting can cause hypovolemic shock. Approximately 1.9 million people worldwide die each year from hemorrhagic shock, with most dying within the first 6 hours.
Centhaquine converts unstressed venous blood volume to stressed blood volume and improves cardiac output and blood circulation, making it an ideal candidate for patient resuscitation. Centhaquine increased cardiac preload and decreased cardiac afterload to increase cardiac output during resuscitation. Patients with uncontrolled bleeding undergo damage control resuscitation to stop blood loss and initiate resuscitation, keeping in mind permissive hypotension targeting a mean arterial pressure of 65 mmHg. Centhaquine resuscitation limits the use of blood, blood products, and vasopressors and provides resuscitation without arterial constriction.
Analysis of randomized controlled trials demonstrated reduced mortality rates attributed to disease conditions rather than new treatment. To our knowledge, this is the only late-stage clinical study that has demonstrated a significant survival benefit, with an 8.8% absolute reduction in mortality. Centhaquine was safe and well tolerated, with no drug-related AEs. A meta-analysis of mortality data obtained from the phase II and III studies as the inclusion criteria were similar and revealed that the mortality was 10.71% in the control group (NOT= 56) and 2.20% in the centhaquine group (NOT= 91) (OR 5.34; 95% CI 1.27–26.50; p= 0.03), which is statistically significant at the 95% CI.
The therapeutic potential of centhaquine in the treatment of other forms of shock associated with hemodynamic instability or refractory hypotension and leading to multiple organ failure and ultimately death is of interest. Some of these conditions may include a distributive shock. Septic shock is a type of distributive shock where a significant change occurs in the vascular compartment and out of the vascular system, resulting in a state of hypovolemia managed by the administration of fluids and vasopressors. Centhaquin increases cardiac preload and reduces cardiac afterload. An increase in cardiac preload may benefit patients in distributive shock by improving microcirculation. The initiation of studies to determine the effectiveness of centhaquine in patients with COVID-19 or septic shock is planned.
Lyfaquin® is a first line therapy used in conjunction with standard of care and is well positioned to meet the critical unmet need for a pharmacologically active resuscitative agent.
About Pharmazz, Inc.
Pharmazz, Inc. is a private company engaged in the development of new products in critical care medicine. Additional information can be found on the Company’s website, www.pharmazz.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations. They involve numerous risks and uncertainties, including the risk that Pharmazz, Inc. may not be able to execute its business plan due to a lack of capital or other resources, distribution, partnership or license/acquisition. Actual events or results may differ materially from those projected in these statements due to a variety of factors. Any of these risks could cause the actual results, levels of activity, performance or achievements of Pharmazz, Inc. or its industry to differ materially from those expressed or implied by the forward-looking statements of this presentation. Pharmazz, Inc. does not intend to update forward-looking statements to conform them to actual results, except as required by applicable law.
Contact
Pharmazz, Inc.
Shruti Gulati
630-780-6087
[email protected]
SOURCEPharmazz, Inc.
Related links
http://www.pharmazz.com
